How does semaglutide behave on a C4 column compared to liraglutide?

Concretely: semaglutide · a C4 column · liraglutide.

These are treated as interchangeable and I do not think they are.

If both are acceptable I would like to know that, so I can stop thinking about it.

Is there a defensible reason to prefer one, or is this a coin flip?

The most important parameter is the one that is almost never specified: the gradient slope during the region where your main peak elutes.

Acetonitrile is the organic modifier of choice because it has a good UV cutoff, a reasonable viscosity and a refractive index that minimises baseline noise.

The relevant detail is that trifluoroacetic acid at 0.1 per cent is the standard ion-pairing agent because it suppresses tailing by neutralising the basic residues, but it also suppresses mass spectrometry signal.

The limitation is that co-elution is invisible — if two species happen to have the same retention time, they will report as a single peak at their combined area.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

Peak shape carries as much information as peak area does, and a badly tailing peak or a shouldered peak is telling you something about the sample or the column that matters.

Sample preparation is almost always under-appreciated — a reconstituted peptide in strong solvent will distort its own peak on the gradient.

Temperature affects both the viscosity of the mobile phase and the dynamics of molecular interactions, and a method developed at 25 degrees and run at 40 degrees will not behave identically.

The selectivity of a reverse-phase separation depends on the hydrophobicity of the side-chain profile, which is why two peptides can co-elute even if they differ by a residue.

One qualification: the limit of detection on a reversed-phase HPLC is set by the noise on the baseline, which for these molecules is usually in the range of a tenth of one per cent or less, and anything smaller is not reproducibly detectable.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.

Worth being precise here: the chemistry of peptides at low pH and high organic-solvent concentration is not something most users have intuition for, which is why published methods exist.

Mobile phase pH at the point where you inject must match the mobile phase pH at the start of the gradient, or the sample will not be focused at the column head.

The caveat is that HPLC is a purity technique and says almost nothing about whether the main peak is actually your target compound — that is why identity confirmation from mass spectrometry or peptide mapping matters.

Ask for the chromatogram and the system suitability data, not just the number.

edited 11 Aug 2024 by otto_brenner — clarified the distinction between purity and content

More usefully, the limit of this technique for these molecules is reaching a point where small improvements require proportionally large investments in method development.

Detector linearity is why a heavily loaded peak can give false purity by compressing the main peak height while leaving impurity shoulders unchanged.

Peptide separation by reverse-phase high-performance liquid chromatography is described in the general chapters of the United States Pharmacopeia, European Pharmacopeia and Japanese Pharmacopeia, and the methods converge on essentially the same principles.

Worth noting that the achievable resolution depends on the chemistry of the molecule — some peptide sequences separate easily while others are notoriously difficult regardless of method.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.